Thumbnail Image
Item

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Amaral, T.
; 
Nanz, L.
; 
Higuita, L. M. S.
; 
Ascierto, P.
; 
Berking, C.
; 
Couselo, E. M.
; 
Donia, M.
; 
Dummer, R.
; 
Gutzmer, R.
; 
Haushild, A.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
BACKGROUND: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies. METHODS: We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software. RESULTS: Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival. CONCLUSION: Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.
Authors
Amaral, T.
Nanz, L.
Higuita, L. M. S.
Ascierto, P.
Berking, C.
Couselo, E. M.
Donia, M.
Dummer, R.
Gutzmer, R.
Haushild, A.
Jalving, M.
Lee, R.
Lorigan, P.
Marquez-Rodas, I.
Michelin, O.
Nathan, P.
Robert, C.
Schadendorf, D.
Sobczuk, P.
Flatz, L.
Leiter, U.
Garbe, C.
Affiliation
Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany. Electronic address: teresa.amaral@med.uni-tuebingen.de. Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany. Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany. Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Instituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutsches Zentrum Immuntherapie and Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuernberg, (CCC ER-EMN), Erlangen, Germany. Vall d'Hebrón Universisty Hospital, Barcelona, Spain & Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain. National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. University Hospital Zurich, Department of Dermatology, Switzerland. Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum, 32429 Minden, Germany. Department of Dermatology, University Hospital (UKSH), Kiel, Germany. Department of Medical Oncology, University Medical Centre Groningen, the Netherlands. Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PL, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK. Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain. Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Mount Vernon Cancer Center, Northwood, UK. Department of Oncology, Institute Gustave Roussy and Paris-Saclay University, Villejiuf, France. Department of Dermatology, Comprehensive Cancer Center (Westdeutsches Tumorzentrum), University Hospital Essen & National Center for Tumor Diseases (NCT-West), Campus Essen & Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, 02-781 Warsaw, Poland. Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Tübingen, Germany.
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Found from Unpaywall
Adobe PDF, 1.63 MB
Keywords
Type
Article
Citation
Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, et al. A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research. European journal of cancer (Oxford, England : 1990). 2025 Jan 17;215:115160. PubMed PMID: 39673834. Epub 2024/12/15. eng.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627431
Embedded videos